INCATE is for innovators fighting drug-resistant bacterial infections with new therapies, development platforms, diagnostics, digital tools and supporting technologies. Our focus geographically is Europe but if you are outside Europe but would like to collaborate please get in contact and we’ll see what we can do.
We want to help you to build investable projects and companies that are ready for the next level of investment from Industry, targeted funds like Carb-X or Novo Repair fund, traditional investors and in some cases further non-dilutive funding.
As of Q1 2022 our focus is on therapies and we are investigating how we can help with diagnostics and devices. Digital tools are not likely to be considered until late 2022 at the earliest (unless you wow us).
To give you an idea of approximate stage, we think we can help most in the following space;
- Drug projects with initial proof of concept and hit/lead identified- (TRL 2-4)
Diagnostic projects that have a POC (TRL 3-4)
Digital tools and other technologies that have a POC from one setting, though the nature of these innovations means it may be harder to set a clear boundary(TRL 3-5)
If you aren’t sure please contact us.
